
At the 2026 AANEM Annual Meeting, Michael Hehir, MD, makes the case that traditional immunotherapy still belongs at the center of long-term myasthenia gravis management, citing outcome data, patient burden, and the costs that often go undiscussed.

At the 2026 AANEM Annual Meeting, Michael Hehir, MD, makes the case that traditional immunotherapy still belongs at the center of long-term myasthenia gravis management, citing outcome data, patient burden, and the costs that often go undiscussed.